Evaluation of Safety and Immunogenicity of Meningococcal and Pneumococcal Vaccines in HIV-Positive Adults: A Randomized, Non-Blinded Clinical Trial

The primary objective of this clinical trial is to evaluate the **safety** and **immunogenicity** of meningococcal and pneumococcal immunization in adult individuals living with **HIV**. This study is clinically relevant as it aims to assess the potential benefits and risks associated with these vaccinations in a population with compromised immune systems, which is crucial for optimizing preventive healthcare strategies in this vulnerable group.

The clinical trial involves participants diagnosed with **HIV**. The study population includes both male and female subjects, with an age range that encompasses categories 3 and 4, indicating a broad spectrum of adult participants. The trial does not specifically target a vulnerable population. The sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, details on the selection process for the trial population, as well as key inclusion or exclusion criteria, have not been disclosed by the sponsor.

The clinical trial is designed as a **randomized** study to evaluate the safety and immunogenicity of meningococcal and pneumococcal immunization among adult individuals living with **HIV**. The trial is non-blinded and will be conducted at a single center. The estimated recruitment start date was April 1, 2021, with an anticipated completion date of December 31, 2027. Participants will be involved in the study for the duration of the trial, unless conditions arise that necessitate early termination, such as adverse reactions or withdrawal of consent.

The sequence of study visits begins with an inclusion visit, where participants are screened for eligibility based on predefined criteria. Following successful screening, participants will be randomized into different study arms. Throughout the trial, participants will attend scheduled follow-up visits to monitor their health status and assess the immunogenic response to the vaccines. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the immunization.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements cannot be provided.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial will assess efficacy through a structured evaluation process. The trial is categorized under Phase II, indicating an intermediate stage of clinical research focused on assessing the efficacy and side effects of the intervention. The trial is scheduled to commence recruitment on April 1, 2021, with an estimated completion date of December 31, 2027. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase II trials typically involve measuring outcomes related to symptom improvement, biomarker levels, or disease remission rates. These assessments are generally conducted using validated scales, laboratory tests, or patient-reported outcomes at predetermined timepoints throughout the trial duration. The data collected will be analyzed to determine the intervention's efficacy in achieving the desired clinical outcomes.